1. IDF21-0111 Intralymphatic GAD-Alum (Diamyd®) improves glycemic control in Type 1 diabetes patients carrying HLA DR3-DQ2. (April 2022) Authors: Ludvigsson, J.; Nowak, C.; Hannelius, U. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IDF21-0113 Design of a precision medicine GAD-alum immunotherapy Phase III clinical trial in Type 1 Diabetes. (April 2022) Authors: Hannelius, U.; Widman, M.; Ludvigsson, J. Journal: Diabetes research and clinical practice Issue: Volume 186:Supplement 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗